GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2020 Earnings Conference Call November 6, 2020 8:30 AM ET Company Participants Shari Annes - IR Rachel King - CEO Brian Hahn - SVP & CFO Helen Thackray - SVP, Clinical Development & CMO John Magnani - Co-Founder & CSO Conference Call Participants Ed White - H.C. Wainwright Ellen Sands - Stifel Zegbeh Jallah - ROTH Capital Partners Operator Good morning and thank you all for joining GlycoMimetics Corporate Update Conference Call. At this time, all participants are in a li ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. Securities registered pursuant to Section 12(b) of the Act: | Title of each clas ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2020 Earnings Conference Call July 31, 2020 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Senior Vice President and Chief Financial Officer Helen Thackray - Senior Vice President, Development and Chief Medical Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Ed White - H.C. Wainwright Biren Amin - Jefferies Stephen Willey - Stifel Operator Good morning and thank you all for jo ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q1 2020 Earnings Conference Call May 1, 2020 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Senior Vice President and Chief Financial Officer Helen Thackray - Senior Vice President, Development and Chief Medical Officer Conference Call Participants Ed White - HC Wainwright Boris Peaker - Cowen Stephen Willey - Stifel Zegbeh Jallah - ROTH Capital Partners Biren Amin - Jefferies Operator Good morning and tha ...

December 2019 | --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------| | | | | | | | CORPORATE | | | | | | OVERVIEW NASDAQ: GLYC | | | | | | | | | | | Innovation Today, Healing Tomorrow. Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding GlycoMimetics, Inc. ("GlycoMimetics," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2019 Earnings Conference Call November 7, 2019 8:30 AM ET Company Participants Shari Annes – Investor Relations Rachel King – Chief Executive Officer Brian Hahn – Senior Vice President and Chief Financial Officer Helen Thackray – Senior Vice President-Development and Chief Medical Officer Conference Call Participants Nirav Shelat – Piper Jaffray Ritu Baral – Cowen Stephen Willey – Stifel Ed White – H.C. Wainwright Operator Good morning, and thank you for joining the Glyc ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2019 Earnings Conference Call August 1, 2019 8:30 AM ET Company Participants Shari Annes - IR Rachel King - President, CEO & Director Brian Hahn - SVP, CFO & Secretary Helen Thackray - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Subhalaxmi Nambi - Cowen and Company Peter Lawson - SunTrust Robinson Humphrey Danielle Brill - Piper Jaffray Companies Stephen Willey - Stifel, Nicolaus & Company Biren Amin - Jefferies Edward White - H.C. Wain ...

(Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended June 30, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q1 2019 Earnings Conference Call May 2, 2019 8:30 AM ET Company Participants Shari Annes - IR Rachel King - President, CEO & Director Brian Hahn - SVP, CFO & Secretary Helen Thackray - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Edward White - H.C. Wainwright & Co. Irina Margine - Cowen and Company Biren Amin - Jefferies Operator Good morning, and thank you all for joining GlycoMimetics First Quarter 2019 Conference Call. [Operator Instruc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...